President Trump issued an executive order on Monday that highlights the long-standing issues surrounding the pricing of prescription drugs in the U.S., where Americans often pay more than people in other countries.
While the specifics of the order remain somewhat unclear, mentioning only future “price targets” and potential enforcement options, the essence of the directive is clear. The U.S. government intends to push back against the inflated drug prices that European governments currently negotiate.
High drug prices have weighed heavily on American consumers, who, in response, can choose leaders willing to change the system.
The executive order tackles the ongoing problem of prescription drug costs in the U.S., primarily driven by the pricing of patented drugs that lack competition, often leading to exorbitant prices.
Pharmaceutical companies now find themselves in a precarious position politically. They benefit from government-granted patent protections, which limit competition and maximize profits from insurance companies and consumers. This isn’t true capitalism. It resembles a blend of legal monopoly and narrow-minded corporate greed. In essence, it’s a classic example of protectionism that intertwines ethical hesitation with relentless profit-seeking.
Though these companies operate legally, they’re on shaky political ground. Americans facing high drug costs are increasingly motivated to vote for candidates who aim to revise the existing laws. Trump’s order is a clear warning: if the public’s frustration grows, Congress will inevitably respond.
The ideal free market encourages competition among businesses striving to provide cheaper, better products. However, when companies create essential goods like life-saving medications, they might deserve a temporary monopoly to recuperate R&D expenses—hence the reason for patents. This aspect of the system is beneficial.
But once the government provides monopoly protections, we step away from a truly free market. This raises a complicated question: Does the government have a responsibility not only to patent holders but also to the consumers who rely on these drugs?
Recently, Stephen Moore, a senior fellow at the Heritage Foundation, weighed in on the debate. He critiqued what he termed “compaginers,” companies that tweak existing drugs and resell them without undergoing similar R&D or FDA approval processes. He labeled these imitations as unsafe and accused them of benefiting from genuine innovation without contributing to it.
These imitation products certainly address market needs, just as the pharmaceutical firms do, but the latter imposes monopoly prices under the shielding of government. Both are cashing in—albeit with fewer legal hurdles.
If the government genuinely wants to enforce patent laws, it must determine whether these monopolies serve the greater public good. Exclusive pricing for critical medications carries ethical ramifications that can’t be ignored.
This leads to another troubling aspect of the situation known as the “last American” approach to drug pricing.
As many Americans struggle to afford medications that could change their lives, pharmaceutical companies often sell the same drugs abroad at a fraction of the U.S. prices. Industry proponents argue that U.S. consumers need to shoulder the bulk of R&D expenses to allow foreign buyers to purchase at lower incremental prices. Without these revenues, they warn, U.S. prices could rise even further.
However, this line of reasoning is shaky.
Charles Lotter recently pointed out that drug pricing in the U.S. acts as a sort of backdoor subsidy for foreign healthcare systems. He questions why American seniors should pay significantly more for identical medications compared to their French counterparts, effectively supporting the French national health system.
Drug pricing transcends mere financial concerns. It underscores a broader failure to prioritize American citizens. Companies might adhere strictly to legal definitions, but they still seem to lack basic loyalty and common sense. This system persists largely because voters have yet to demand change. Trump’s executive order signals a shift is underway.
Congress could enhance this situation by re-evaluating patent protections and insisting on greater price transparency. The message to the pharmaceutical industry needs to be loud and clear: they can either act as responsible corporate citizens and stop draining patients, or they can wait for the government to take action.
If pharmaceutical firms continue to exploit their monopolies, they shouldn’t be caught off guard when voters and their representatives decide to counteract their practices.
